[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Artiva Biotherapeutics Inc (ARTV)

Artiva Biotherapeutics Inc (ARTV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 552,457
  • Shares Outstanding, K 48,890
  • Annual Sales, $ 0 K
  • Annual Income, $ -83,870 K
  • EBIT $ -96 M
  • EBITDA $ -94 M
  • 60-Month Beta 2.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.56

Options Overview Details

View History
  • Implied Volatility 135.81% (-8.43%)
  • Historical Volatility 50.01%
  • IV Percentile 17%
  • IV Rank 29.49%
  • IV High 222.31% on 07/24/26
  • IV Low 99.63% on 08/24/26
  • Expected Move (DTE 17) 0.30 (2.65%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 250
  • Volume Avg (30-Day) 53
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 719
  • Open Int (30-Day) 467
  • Expected Range 10.94 to 11.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.54
  • Number of Estimates 3
  • High Estimate $-0.53
  • Low Estimate $-0.56
  • Prior Year $-0.88
  • Growth Rate Est. (year over year) +38.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.90 +14.04%
on 08/03/26
12.27 -7.99%
on 08/11/26
+1.19 (+11.78%)
since 07/31/26
3-Month
6.59 +71.32%
on 06/02/26
12.27 -7.99%
on 08/11/26
+3.83 (+51.34%)
since 06/01/26
52-Week
2.22 +408.56%
on 09/17/25
14.53 -22.30%
on 04/20/26
+8.14 (+258.41%)
since 08/29/25

Most Recent Stories

More News
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK ® ’s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive...

ARTV : 11.28 (-0.18%)
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to...

ARTV : 11.28 (-0.18%)
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies...

ARTV : 11.28 (-0.18%)
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to...

ARTV : 11.28 (-0.18%)
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies...

ARTV : 11.28 (-0.18%)
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis...

ARTV : 11.28 (-0.18%)
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today...

ARTV : 11.28 (-0.18%)
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies...

ARTV : 11.28 (-0.18%)
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference...

ARTV : 11.28 (-0.18%)
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases

Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients with...

ARTV : 11.28 (-0.18%)

Business Summary

Artiva Biotherapeutics Inc. is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. The company's lead program includes AlloNK(R). Artiva Biotherapeutics Inc. is based in SAN DIEGO....

See More

Key Turning Points

3rd Resistance Point 11.94
2nd Resistance Point 11.65
1st Resistance Point 11.47
Last Price 11.28
1st Support Level 11.00
2nd Support Level 10.71
3rd Support Level 10.53

See More

52-Week High 14.53
Last Price 11.28
Fibonacci 61.8% 9.83
Fibonacci 50% 8.38
Fibonacci 38.2% 6.92
52-Week Low 2.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.